Chemotherapeutic agents for the treatment of metastatic breast cancer: An update

Mariam Abotaleb, Peter Kubatka, Martin Caprnda, Elizabeth Varghese, Barbora Zolakova, Pavol Zubor, Radka Opatrilova, Peter Kruzliak, Patrik Stefanicka, Dietrich Busselberg

Research output: Contribution to journalReview article

24 Citations (Scopus)

Abstract

Breast cancer is the second greatest cause of death among women worldwide; it comprises a group of heterogeneous diseases that evolves due to uncontrolled cellular growth and differentiation and the loss of normal programmed cell death. There are different molecular sub-types of breast cancer; therefore, various options are selected for treatment of different forms of metastatic breast cancer. However, the use of chemotherapeutic drugs is usually accompanied by deleterious side effects and the development of drug resistance when applied for a longer period. This review offers a classification of these chemotherapeutic agents according to their modes of action and therefore improves the understanding of molecular targets that are affected during treatment. Overall, it will allow the clinician to identify more specific targets to increase the effectiveness of a drug and to reduce general toxicity, resistance and other side effects.

Original languageEnglish
Pages (from-to)458-477
Number of pages20
JournalBiomedicine and Pharmacotherapy
Volume101
DOIs
Publication statusPublished - 1 May 2018

Fingerprint

Breast Neoplasms
Drug-Related Side Effects and Adverse Reactions
Drug Resistance
Pharmaceutical Preparations
Cause of Death
Cell Death
Therapeutics
Growth

Keywords

  • Antimetabolites
  • Antimitotic agents
  • Chemotherapy
  • DNA alkylating agents
  • Efficacy
  • Hormonal/endocrine therapy
  • Immunologic therapy
  • Ion modulators
  • Metastatic breast cancer
  • Resistance
  • Toxicity

ASJC Scopus subject areas

  • Pharmacology

Cite this

Chemotherapeutic agents for the treatment of metastatic breast cancer : An update. / Abotaleb, Mariam; Kubatka, Peter; Caprnda, Martin; Varghese, Elizabeth; Zolakova, Barbora; Zubor, Pavol; Opatrilova, Radka; Kruzliak, Peter; Stefanicka, Patrik; Busselberg, Dietrich.

In: Biomedicine and Pharmacotherapy, Vol. 101, 01.05.2018, p. 458-477.

Research output: Contribution to journalReview article

Abotaleb, M, Kubatka, P, Caprnda, M, Varghese, E, Zolakova, B, Zubor, P, Opatrilova, R, Kruzliak, P, Stefanicka, P & Busselberg, D 2018, 'Chemotherapeutic agents for the treatment of metastatic breast cancer: An update', Biomedicine and Pharmacotherapy, vol. 101, pp. 458-477. https://doi.org/10.1016/j.biopha.2018.02.108
Abotaleb, Mariam ; Kubatka, Peter ; Caprnda, Martin ; Varghese, Elizabeth ; Zolakova, Barbora ; Zubor, Pavol ; Opatrilova, Radka ; Kruzliak, Peter ; Stefanicka, Patrik ; Busselberg, Dietrich. / Chemotherapeutic agents for the treatment of metastatic breast cancer : An update. In: Biomedicine and Pharmacotherapy. 2018 ; Vol. 101. pp. 458-477.
@article{25c862b4af494ba597a20619217922b9,
title = "Chemotherapeutic agents for the treatment of metastatic breast cancer: An update",
abstract = "Breast cancer is the second greatest cause of death among women worldwide; it comprises a group of heterogeneous diseases that evolves due to uncontrolled cellular growth and differentiation and the loss of normal programmed cell death. There are different molecular sub-types of breast cancer; therefore, various options are selected for treatment of different forms of metastatic breast cancer. However, the use of chemotherapeutic drugs is usually accompanied by deleterious side effects and the development of drug resistance when applied for a longer period. This review offers a classification of these chemotherapeutic agents according to their modes of action and therefore improves the understanding of molecular targets that are affected during treatment. Overall, it will allow the clinician to identify more specific targets to increase the effectiveness of a drug and to reduce general toxicity, resistance and other side effects.",
keywords = "Antimetabolites, Antimitotic agents, Chemotherapy, DNA alkylating agents, Efficacy, Hormonal/endocrine therapy, Immunologic therapy, Ion modulators, Metastatic breast cancer, Resistance, Toxicity",
author = "Mariam Abotaleb and Peter Kubatka and Martin Caprnda and Elizabeth Varghese and Barbora Zolakova and Pavol Zubor and Radka Opatrilova and Peter Kruzliak and Patrik Stefanicka and Dietrich Busselberg",
year = "2018",
month = "5",
day = "1",
doi = "10.1016/j.biopha.2018.02.108",
language = "English",
volume = "101",
pages = "458--477",
journal = "Biomedicine and Pharmacotherapy",
issn = "0753-3322",
publisher = "Elsevier Masson",

}

TY - JOUR

T1 - Chemotherapeutic agents for the treatment of metastatic breast cancer

T2 - An update

AU - Abotaleb, Mariam

AU - Kubatka, Peter

AU - Caprnda, Martin

AU - Varghese, Elizabeth

AU - Zolakova, Barbora

AU - Zubor, Pavol

AU - Opatrilova, Radka

AU - Kruzliak, Peter

AU - Stefanicka, Patrik

AU - Busselberg, Dietrich

PY - 2018/5/1

Y1 - 2018/5/1

N2 - Breast cancer is the second greatest cause of death among women worldwide; it comprises a group of heterogeneous diseases that evolves due to uncontrolled cellular growth and differentiation and the loss of normal programmed cell death. There are different molecular sub-types of breast cancer; therefore, various options are selected for treatment of different forms of metastatic breast cancer. However, the use of chemotherapeutic drugs is usually accompanied by deleterious side effects and the development of drug resistance when applied for a longer period. This review offers a classification of these chemotherapeutic agents according to their modes of action and therefore improves the understanding of molecular targets that are affected during treatment. Overall, it will allow the clinician to identify more specific targets to increase the effectiveness of a drug and to reduce general toxicity, resistance and other side effects.

AB - Breast cancer is the second greatest cause of death among women worldwide; it comprises a group of heterogeneous diseases that evolves due to uncontrolled cellular growth and differentiation and the loss of normal programmed cell death. There are different molecular sub-types of breast cancer; therefore, various options are selected for treatment of different forms of metastatic breast cancer. However, the use of chemotherapeutic drugs is usually accompanied by deleterious side effects and the development of drug resistance when applied for a longer period. This review offers a classification of these chemotherapeutic agents according to their modes of action and therefore improves the understanding of molecular targets that are affected during treatment. Overall, it will allow the clinician to identify more specific targets to increase the effectiveness of a drug and to reduce general toxicity, resistance and other side effects.

KW - Antimetabolites

KW - Antimitotic agents

KW - Chemotherapy

KW - DNA alkylating agents

KW - Efficacy

KW - Hormonal/endocrine therapy

KW - Immunologic therapy

KW - Ion modulators

KW - Metastatic breast cancer

KW - Resistance

KW - Toxicity

UR - http://www.scopus.com/inward/record.url?scp=85042646206&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042646206&partnerID=8YFLogxK

U2 - 10.1016/j.biopha.2018.02.108

DO - 10.1016/j.biopha.2018.02.108

M3 - Review article

C2 - 29501768

AN - SCOPUS:85042646206

VL - 101

SP - 458

EP - 477

JO - Biomedicine and Pharmacotherapy

JF - Biomedicine and Pharmacotherapy

SN - 0753-3322

ER -